Market Overview

UPDATE: Morgan Stanley Reiterates On Cardinal Health Following CEO Conference Call

Share:
Related CAH
Benzinga's M&A Chatter for Monday March 2, 2015
'Merger Monday' Lives Up To Name: From NXP Semiconductors To eBay, There's At Least $20 Billon In Total Deals
PharMerica re-ups with Cardinal Health (Seeking Alpha)

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Cardinal Health (NYSE: CAH), but removed the $76.00 price target.

In the report, Morgan Stanley noted, “Utilization trends likely positive for pharmaceutical segment; medical trends less clear. While George [Barrett, Cardinal Health CEO] did not comment on current quarter trends, he acknowledged that IMS Rx data (pointing to an improving trend for NRx in April) serves as a good proxy to assess directional script trends for CAH & large wholesalers.

"Conversely, medical segment is not well correlated with IMS data. CAH expects to continue to see fluctuations in segment demand driven by benefit design and greater consumer accountability.”

Cardinal Health closed on Tuesday at $71.10.

Latest Ratings for CAH

DateFirmActionFromTo
Feb 2015Morgan StanleyDowngradesOverweightEqual-weight
Jan 2015Deutsche BankMaintainsHold
Jan 2015CitigroupMaintainsNeutral

View More Analyst Ratings for CAH
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CAH)

Around the Web, We're Loving...

Get Benzinga's Newsletters